Analysts See FDA Spurning New Merck Arthritis Drug Industry analysts are predicting US regulators this month will refuse to approve Merck  amp; Co. #39;s new arthritis drug until at least 2006 because of heart attacks linked to its recalled sister drug Vioxx.